Shares of Adma Biologics (ADMA) have gained 18.9% over the past four weeks to close the last trading session at 5.23,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof6.88 indicates a potential upside of 31.6%.The average comprises four short-term price targets ranging from a low of 6toahighof9, with a standard deviation of $1.44. While the lowest estimate indicates an i ...